Evidence map›Paper›PMID 39636551›Full record

ArticleJournal of neuro-oncology2025

Single-cell RNA-seq reveals diverse molecular signatures associated with Methotrexate resistance in primary central nervous system lymphoma cells.

Ryosuke Osako, Azusa Hayano, Atsushi Kawaguchi, Ryuya Yamanaka

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Ryosuke OsakoEducation and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Azusa HayanoLaboratory of Molecular Target Therapy for Cancer, Graduate School for Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Kamigyoku, Kyoto, 602-8566, Japan.
Atsushi KawaguchiEducation and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Ryuya YamanakaLaboratory of Molecular Target Therapy for Cancer, Graduate School for Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Kamigyoku, Kyoto, 602-8566, Japan. ryaman@koto.kpu-m.ac.jp.

Funding

Japan Society for the Promotion of Science JP21H03045 and JP16H06279 (PAGS)
6 · The paper itself

Abstract

purposeMethotrexate is one of the most essential single agents in patients with primary central nervous system lymphoma (PCNSL). However, 25-50% result in relapse with a poor prognosis. Therefore, studies on methotrexate resistance are warranted to explore salvage chemotherapy for recurrent PCNSL. Single-cell sequence analysis enables the characterization of novel cell types and provides a precise understanding of cancer biology.

methodsSingle-cell sequence analysis of parental and methotrexate-resistant PCNSL cells was performed. We used a Weighted Gene Co-expression Network Analysis to identify groups of significantly connected genes.

resultsWe identified consensus modules in both the HKBML and TK datasets. HLA-DRβ1, HLA-DQβ1,and SNRPG were hub genes those detected in both datasets revealed by network analysis. Cyclosporine A was selected as the candidate drug for treating methotrexate-resistant cells.

conclusionThe results of the present study characterized the methotrexate resistance-related signaling pathways in cultured PCNSL cells. Overall, these results may account for variations in treatment responses and lead potential novel therapeutic strategies for patients with PCNSL.

Indexed as

Antimetabolites, AntineoplasticBiomarkers, TumorCentral Nervous System NeoplasmsDrug Resistance, NeoplasmLymphomaMethotrexateSingle-Cell AnalysisGene Expression Regulation, NeoplasticHumansRNA-SeqSingle-Cell Gene Expression AnalysisAntimetabolites, AntineoplasticBiomarkers, TumorMethotrexateCyclosporine AMethotrexate resistancePrimary central nervous system lymphomaSingle-cell transcriptome analyses

Identifiers

PMID39636551

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.